Avelumab
- Generic Name
- Avelumab
- Brand Names
- Bavencio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1537032-82-8
- Unique Ingredient Identifier
- KXG2PJ551I
- Background
Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year, it was also granted approval by EMA and Health Canada, res...
- Indication
Avelumab is indicated for the treatment of adults with metastatic Merkel cell carcinoma (MCC). In the US, it is also used in patients 12 years and older.
...
- Associated Conditions
- Advanced Renal Cell Carcinoma, Metastatic Urothelial Cancer, Locally advanced Urothelial Carcinoma, Metastatic Merkel Cell Carcinoma (MCC)
- Associated Therapies
- First Line Chemotherapy, Maintenance therapy
Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)
- Conditions
- Interventions
- First Posted Date
- 2015-01-29
- Last Posted Date
- 2021-06-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 65
- Registration Number
- NCT02349633
- Locations
- 🇺🇸
UPMC Cancer Pavilion, Pittsburgh, Pennsylvania, United States
🇺🇸UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇦🇺Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)
- First Posted Date
- 2014-06-04
- Last Posted Date
- 2024-03-13
- Target Recruit Count
- 204
- Registration Number
- NCT02155647
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇮🇹Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
🇮🇹Arcispedale S. Maria Nuova Azienda Ospedaliera di Reggio Emilia, Reggio Emilia, Italy
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
- First Posted Date
- 2013-01-21
- Last Posted Date
- 2021-12-20
- Target Recruit Count
- 1756
- Registration Number
- NCT01772004
- Locations
- 🇺🇸
Cancer Treatment Centers of America - Western Regional Medical Center, Goodyear, Arizona, United States
🇺🇸Highlands Oncology Group, Rogers, Arkansas, United States
🇺🇸California Cancer Associates for Research & Excellence, Inc, Encinitas, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.